2. PROTAC GPCR/G Protein MAPK/ERK Pathway
  3. PROTACs Ras
  4. KRAS G12D inhibitor 17

KRAS G12D inhibitor 17 (example 8) is a quinazoline-linked (4R)-4-hydroxy-L-prolinamide compound, inducing degradation of G12D-mutation KRAS protein. KRAS G12D inhibitor 17 is a PROTAC.

For research use only. We do not sell to patients.

KRAS G12D inhibitor 17 Chemical Structure

KRAS G12D inhibitor 17 Chemical Structure

CAS No. : 2821793-99-9

Size Price Stock Quantity
1 mg USD 1250 Get quote 14 - 16 weeks 13 - 15 weeks
5 mg USD 2503 Get quote 14 - 16 weeks 13 - 15 weeks
10 mg USD 4008 Get quote 14 - 16 weeks 13 - 15 weeks
25 mg USD 8015 Get quote 14 - 16 weeks 13 - 15 weeks
50 mg USD 12425 Get quote 14 - 16 weeks 13 - 15 weeks
100 mg USD 19250 Get quote 14 - 16 weeks 13 - 15 weeks
200 mg   Get quote  
500 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

KRAS G12D inhibitor 17 Related Antibodies

Top Publications Citing Use of Products

View All PROTACs Isoform Specific Products:

View All Isoforms
von Hippel-Lindau (VHL) Cereblon MDM2 cIAP1

View All Ras Isoform Specific Products:

View All Isoforms
K-Ras H-Ras Ras

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

KRAS G12D inhibitor 17 (example 8) is a quinazoline-linked (4R)-4-hydroxy-L-prolinamide compound, inducing degradation of G12D-mutation KRAS protein. KRAS G12D inhibitor 17 is a PROTAC[1].

IC50 & Target

KRAS(G12D)

 

Molecular Weight

1117.30

Formula

C60H65FN12O7S
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CC(C(C(C(C1CC1)=CC(C(N2[C@@](CN3)([H])C[C@@]3([H])C2)=N4)=C5N=C4OC6CCOCC6)=C5OCC7=CC=C(C(N=N8)=CN8[C@@H](C(C)C)C(N(C[C@@H]9O)[C@@H](C9)C(N[C@H](C%10=CC=C(C(SC=N%11)=C%11C)C=C%10)CO)=O)=O)C=C7)=C(C=NN%12)C%12=C%13)=C%13F
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

KRAS G12D inhibitor 17 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KRAS G12D inhibitor 172821793-99-9PROTACsRasquinazoline-linked (4R)-4-hydroxy-L-prolinamide compoundprotein degradationG12D-mutationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
KRAS G12D inhibitor 17
Cat. No.:
HY-148273
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.